PC
VRTX icon

Polar Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Polar Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$61.2M Buy
225,037
+53,700
+31% +$14.8M 0.45% 63
2020
Q2 		$49.7M Buy
171,337
+76,337
+80% +$20.7M 0.43% 72
2020
Q1 		$22.6M Sell
95,000
-5,000
-5% -$1.15M 0.24% 118
2019
Q4 		$21.9M Sell
100,000
-25,000
-20% -$5.06M 0.19% 145
2019
Q3 		$21.2M Sell
125,000
-50,000
-29% -$8.85M 0.19% 141
2019
Q2 		$32.1M Buy
175,000
+10,000
+6% +$1.75M 0.28% 114
2019
Q1 		$30.4M Buy
165,000
+40,000
+32% +$7.39M 0.28% 123
2018
Q4 		$20.7M Sell
125,000
-95,000
-43% -$16.5M 0.22% 132
2018
Q3 		$42.4M Buy
220,000
+45,000
+26% +$8.01M 0.36% 88
2018
Q2 		$29.7K Sell
175,000
-317,500
-64% -$49.2M 0.18% 119
2018
Q1 		$80.3M Buy
492,500
+275,000
+126% +$44.9M 0.81% 25
2017
Q4 		$32.6M Buy
217,500
+101,000
+87% +$15M 0.34% 96
2017
Q3 		$17.7M Buy
116,500
+66,500
+133% +$10M 0.2% 132
2017
Q2 		$6.44M Buy
50,000
+35,000
+233% +$4.21M 0.09% 175
2017
Q1 		$1.64M Hold
15,000
– – 0.02% 240
2016
Q4 		$1.1M Sell
15,000
-3,500
-19% -$285K 0.02% 245
2016
Q3 		$1.61M Sell
18,500
-11,181
-38% -$1.06M 0.03% 228
2016
Q2 		$2.55M Buy
29,681
+16,768
+130% +$1.45M 0.05% 212
2016
Q1 		$1.03M Sell
12,913
-5,290
-29% -$478K 0.02% 234
2015
Q4 		$2.29M Sell
18,203
-324
-2% -$39.1K 0.04% 209
2015
Q3 		$1.93M Buy
18,527
+8,671
+88% +$1.11M 0.04% 219
2015
Q2 		$1.22M Sell
9,856
-6,733
-41% -$848K 0.02% 247
2015
Q1 		$1.96M Buy
16,589
+12,260
+283% +$1.47M 0.04% 220
2014
Q4 		$514K Buy
+4,329
New +$488K 0.01% 259

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Polar Capital's VRTX Position: Q3 2020 in Review

Polar Capital increased its Vertex Pharmaceuticals (VRTX) stake by 31% in Q3 2020, buying an estimated $14.8M and bringing the position to 225,037 shares worth $61.2M. The position accounts for 0.45% of the portfolio, ranked #63.

Polar Capital first reported a position in VRTX in Q4 2014 and has held it in 24 quarters since. The position peaked at $80.3M in Q1 2018. 950 funds tracked by Wall St. Rank hold VRTX as of Q3 2020.

  • Polar Capital held 225,037 shares of Vertex Pharmaceuticals worth $61.2M as of Q3 2020.
  • Polar Capital bought 53,700 Vertex Pharmaceuticals shares in Q3 2020, an estimated $14.8M.
  • Vertex Pharmaceuticals made up 0.45% of Polar Capital's portfolio in Q3 2020, its #63 holding.
  • Polar Capital first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 24 quarters since.
  • Polar Capital's Vertex Pharmaceuticals position peaked at $80.3M in Q1 2018.
  • 950 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2020.

Based on Polar Capital's 13F filing for Q3 2020, filed 16 Nov 2020.